NCT06525311 - A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

March 12, 2025

Study Completion Date

April 9, 2025

Conditions

Primary Biliary CholangitisCompensated Cirrhosis

Interventions

DRUG

K-808

K-808 single or multi dose extended-release tablets

Trial Locations (10)

Indiana University School of Medicine - Indianapolis, Indianapolis

Houston Research Institute, Houston

Texas Liver Institute, San Antonio

Arizona Liver Health, Chandler

Southern California Research Center, Inc, Coronado

Pinnacle Clinical Research, San Antonio

303, Fukuoka

302, Kita-gun

304, Shinjuku-ku

301, Yufu